Clinical Outcomes of Patients with LAL+ in At Least One Eye
- Conditions
- IOL, Cataract
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Frank A. Bucci, Jr., M.D.
- Target Recruit Count
- 25
- Registration Number
- NCT06650358
- Locations
- ๐บ๐ธ
Bucci Laser Vision Institute, Wilkes-Barre, Pennsylvania, United States
Pharmacokinetics of Aqueous Dexamethasone
Phase 4
Completed
- Conditions
- PharmacokineticsAqueous DexamethasoneInflammatory Cytokine Response
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Frank A. Bucci, Jr., M.D.
- Target Recruit Count
- 102
- Registration Number
- NCT04667507
- Locations
- ๐บ๐ธ
Bucci Laser Vision, Wilkes-Barre, Pennsylvania, United States
Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Frank A. Bucci, Jr., M.D.
- Target Recruit Count
- 120
- Registration Number
- NCT01296191
- Locations
- ๐บ๐ธ
Bucci Laser Vision Institute, Wilkes-Barre, Pennsylvania, United States
Evaluation the TECNIS IOL in Both Eyes VS the ReZoom IOL in One and TECNIS IOL in the Opposite
Completed
- Conditions
- Cataract
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Frank A. Bucci, Jr., M.D.
- Target Recruit Count
- 175
- Registration Number
- NCT01253239
- Locations
- ๐บ๐ธ
Bucci Laser Vision Institute, Wilkes-Barre, Pennsylvania, United States
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
Phase 4
Completed
- Conditions
- Cataracts
- Interventions
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- Frank A. Bucci, Jr., M.D.
- Target Recruit Count
- 126
- Registration Number
- NCT01021761
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
Phase 4
Completed
- Conditions
- Cataracts
- Interventions
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2011-10-03
- Lead Sponsor
- Frank A. Bucci, Jr., M.D.
- Target Recruit Count
- 126
- Registration Number
- NCT01001806
- Locations
- ๐บ๐ธ
Bucci Laser Vision Institute, Wilkes-Barre, Pennsylvania, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath